| Placebo | Active | p |
---|---|---|---|
HTLV-I proviral loada (log10 copies/105 PBMCs) | +0.03 (0.10) | +0.05 (0.13) | 0.92 |
Total Lymphocytesb (106/L) | +148.2 (58.0) | -159.3 (146.7) | 0.07 |
CD3 Lymphocytesb (106/L) | +98.4 (63.4) | -23.2 (151.3) | 0.47 |
CD3b % | +0.2 (2.8) | +4.3 (2.6) | 0.14 |
CD4b Lymphocytes (106/L) | +32.6 (33.1) | +10.4 (98.7) | 0.55 |
CD4b % | -1.2 (0.9) | +4.7 (1.8) | 0.01 |
CD8b Lymphocytes (106/L) | +65.8 (31.3) | -38.1 (60.7) | 0.15 |
CD8b % | +1.4 (1.2) | +1.4 (1.9) | 0.99 |
CD25a % | -0.8 (1.8) | +0.3 (0.8) | 0.58 |
CD69a % | +0.4 (1.3) | +1.2 (1.8) | 0.73 |
CD71a% | -0.3 (1.0) | -0.2 (1.9) | 0.97 |
HLA-DR% | -4.85 (4.0) | +3.59 (2.4) | 0.42 |